Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
59,964,750
-
Total 13F shares
-
49,022,523
-
Share change
-
+827,405
-
Total reported value
-
$933,879,055
-
Put/Call ratio
-
84%
-
Price per share
-
$19.05
-
Number of holders
-
134
-
Value change
-
+$18,597,011
-
Number of buys
-
69
-
Number of sells
-
54
Institutional Holders of Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) as of Q2 2018
As of 30 Jun 2018,
Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) was held by
134 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,022,523 shares.
The largest 10 holders included
BlackRock Inc., Consonance Capital Management LP, Palo Alto Investors LP, VANGUARD GROUP INC, venBio Select Advisor LLC, MACQUARIE GROUP LTD, ARMISTICE CAPITAL, LLC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
134
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.